Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

Condition:   Alzheimer's DiseaseInterventions:   Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: PlaceboSponsors:   GlaxoSmithKline;   GlaxoSmithKlineCompleted - verified May 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials